| Methods | n = 25 Allocation concealment: not described Baseline similarity: age, APACHE II Blinding: caregivers Cointerventions: not described Withdrawals: none Losses to follow‐up: none |
|
| Participants | Inclusions: Risk factor for ARDS; diffuse CXR infiltrates, P/F ratio < 285 mmHg, no cardiogenic pulmonary edema | |
| Interventions | IV neutrophil elastase inhibitor (ICI 200,880), 350mg for up to 14 days, or placebo | |
| Outcomes | Mortalilty: RR 0.27 (95% CI 0.04 to 2.10) | |
| Notes | Published as abstract only | |
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Allocation concealment (selection bias) | Unclear risk | B ‐ Unclear |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.